[665] in Project_DB
new stock
daemon@ATHENA.MIT.EDU (Fanny Dickey)
Mon Mar 10 11:08:48 2003
From: "Fanny Dickey" <climbsflouncepossesso@let.uu.nl>
Message-ID: <NATORZKQNOOUFTBIVDVKKWAOOXXNJW@59.165.90.25>
To: leonardm@mit.edu
Date: Mon, 10 Mar 03 10:58:58 GMT
MIME-Version: 1.0
Content-Type: multipart/alternative; boundary=FLMCUNERPKHEOIQLU
This is a multi-part message in MIME format.
--FLMCUNERPKHEOIQLU
Content-Type: text/html
Content-Transfer-Encoding: 7Bit
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<title>RJVN</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>
<body leftmargin="0" topmargin="0" bgproperties="fixed">
<table width="500" border="0" align="left">
<tr align="left" valign="top">
<td colspan="2"><div align="center">
<p align="center"><a
href="mailto:asianprince@pekingtrail.com.ph?subject=RJVN"><strong>Click
here for more information on RJVN</strong></a></p>
<p align="center"><a
href="mailto:asianprince@pekingtrail.com.ph?subject=Remove"><font size="2">Click
here to remove your email address from our
database.</font></a><br>
</p>
</div></td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td><font size="2"><strong>Congratulations to all investors who have
taken
some initiative and started getting back into the market, as some
very
nice gains were realized with JUNI (our last featured company,
December
2002) going from .36 cents to over $ 1.10 for an incredible 300%
gain
over the last several weeks if you played it right!!! We are even
more
excited about this latest opportunity as it features a company in
an extraordinary
industry!!! </strong></font><font size="2"><strong><br>
<br>
RJV Network Inc. OTCBB: RJVN</strong> ( through BioKinetix Research
Inc
) in conjunction with BioCurex Inc. is behind the development of a
new
therapeutic product, which experts believe will arrest the
development
of and replication of cancerous cells that cause the growth of
malignant
tumors. . . <strong>Symbol: RJVN (OTCBB) . Current price:
.15</strong></font>
</td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td> </td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td><strong><font size="2">Overview:</font></strong><font
size="2"><br>
This is a brief background of<strong> BioKinetix Research
Inc.</strong>
The company was formed after Dr, John Todd, a very well known and
respected
oncological surgeon from BC, approached us with the story of an
astounding
discovery that had been made by molecular biologists at the
university
of Michigan. This discovery was believed to be the causal link to
breast
cancer, the link is a medium sized (53KD) protein called
Mammastatin.
The evidence is that Mammastatin is the agent that, when present,
prevents
the development of and growth of malignant breast tumors.
Mammastatin
is freely expressed by the epithelial cells in the breast and as
such
acts as a natural contra-agent to malignant development. Women who
develop
breast cancer have NO, or extremely low levels of, Mammastatin in
their
system. After testing hundreds of women, no women with normal
levels of
Mammastatin levels has developed breast cancer. </font></td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td> </td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td><font size="2"><strong>The Opportunity and Market: <br>
</strong></font> <table width="100%" border="0">
<tr>
<td width="2%" align="left" valign="top"> </td>
<td width="98%"><font size="2"><strong>BioKinetix</strong> has
proprietary
technology for developing “superantibodies” that
make
ordinary antibodies vastly more effective. </font></td>
</tr>
<tr>
<td align="left" valign="top"> </td>
<td><font size="2"><strong>BioCurex </strong>has the cancer
markers
that identify the cancer cells and RJV networks –
BioKinetix
hes the superantibody technology to kill them. </font></td>
</tr>
<tr>
<td align="left" valign="top"> </td>
<td><font size="2"><strong>Dr. John Todd,</strong> in
conjunction
with the Cancer Control Agency of B.C. conducted
compassionate trials
on several terminally ill patients (authorized by health
Canada)
with a Mammastatin replacement program the results of which
thoroughly
convinced Dr. Todd of the direct link </font></td>
</tr>
<tr>
<td align="left" valign="top"> </td>
<td><font size="2"><strong>BioKinetix</strong> will be using
network
research that eliminates the necessity for major capital
expenditures
in the areas of pathology, laboratory research and ultimately
in
the clinical level. </font></td>
</tr>
<tr>
<td align="left" valign="top"> </td>
<td> </td>
</tr>
</table></td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td><font size="2"><strong>Conclusion:<br>
</strong>“We believe that this company has the capacity to
reach
Genentech size within a few years. Genentech ( NYSE:DNA ) presently
trades
around the $40 level with a market cap of between 40 and 50 billion
dollars.
This speculation is attainable through the unique business model
created
by BioKinetix research Inc.” <br>
<strong>Dr. John Todd, President of BioKinetix Research
Inc.</strong>
</font></td>
</tr>
<tr align="left" valign="top">
<td colspan="2"> </td>
</tr>
<tr align="left" valign="top">
<td colspan="2"><br> <font size="2">Except for historical matters
contained
herein, the matters discussed are forward-looking and are made
pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform
Act of 1995. Investors are cautioned that these forward-looking
statements
reflect numerous assumptions and involve risk and uncertainties
that may
affect Juniper Group, Inc. and its subsidiaries business and
prospects
and cause actual results to differ materially from these
forward-looking
statements. Among the factors that could cause actual results to
differ
are Juniper Group, Inc.'s operating history; competition; low
barriers
to entry; reliance on strategic relationships; rapid technological
changes;
inability to complete transactions on favorable terms; and those
risks
discussed in the Company's filings with the SEC. Before making any
investment
decisions, the Investor should review the Company’s recent
SEC filings.<br>
</font> </td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td> </td>
</tr>
</table>
</div>
</body>
</html>
ZbyaVxPjtZTzpvYigrI
--FLMCUNERPKHEOIQLU--
